Bossage Genetics

1. Evaluate the relative bioavailability of 4.0 mg/mL and 10.0 mg/mL formulations of Yipei growth hormone injection in healthy subjects after single subcutaneous injection; 2. Evaluate the pharmacokinetic (PK) characteristics and immunogenicity of 4.0 mg/mL and 10.0 mg/mL formulations of Yipei growth hormone injection in healthy subjects; 3. Evaluate the safety of 4.0 mg/mL and 10.0 mg/mL formulations of Yipei growth hormone injection in healthy subjects;

Explore the safety and tolerability of the experimental drug (Y-type PEGylated recombinant human growth hormone injection, Yipeisheng) in the elderly population, as well as its pharmacokinetic and pharmacodynamic characteristics, to provide a basis for subsequent clinical research.

1. Conduct dose exploration to determine the optimal dosing regimen for the experimental drug Y-PEGylated recombinant human growth hormone injection in the treatment of children with GHD; 2. Evaluate the safety and efficacy of the experimental drug Y-PEGylated recombinant human growth hormone injection and the positive control drug in the treatment of growth hormone deficiency in children, and provide a basis for the drug to be marketed.